Newsletters

[HepaRegeniX (GlobeNewswire)] HepaRegeniX announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally available small-molecule inhibitor of MKK4, in patients undergoing partial liver resection due to liver metastases deriving from colorectal cancer.

[AbbVie ] AbbVie announced that the US FDA approved a label expansion for MAVYRET^®, an oral pangenotypic direct acting antiviral therapy. It is now approved for the treatment of adults and pediatric patients three years and older with acute or chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis.

[Development] Researchers presented an approach for rapid engineering of multiple inducible systems into mESCs. Small molecule- and cell contact-inducible systems work reliably and efficiently for controlling expression of arbitrary genetic payloads.

[Proceedings of The National Academy of Sciences of The United States of America] Scientists developed a supramolecular hydrogel, enabling the codelivery and sequential release of hydrophilic and lipophilic drugs designed to target the ECM.

[Nature Cancer] Scientists review immune and non-immune cellular components of the TME that regulate adaptive cell responses and their role in immune checkpoint blockade response and resistance.

[Stem Cell Reviews and Reports] The authors review the role of Wnt10b signaling in hair growth and regeneration. During embryonic development, Wnt10b promotes hair morphogenesis by inducing the formation of dermal papilla.

[Cell Death Discovery] The authors summarize current knowledge on both physiological and pathological roles of MAFB and highlight the impact of its deregulation on hematological cancer initiation and progression.

[Cell] In a 44-week trial, scientists intravenously delivered senescence-resistant human mesenchymal progenitor cells to aged macaques, noting a systemic reduction in aging indicators, such as cellular senescence, chronic inflammation, and tissue degeneration, without any detected adverse effects.

[Acta Pharmaceutica Sinica B] Investigators showed that the expression of calnexin was significantly increased in hepatitis B virus-associated liver cancer, and its upregulation was relevant to the unfavorable survival of patients with the tumor.

[Nature Medicine] DUET was a 12-week, randomized, double-blind, placebo-controlled, multicenter Phase IIa study investigating the efficacy, safety, and pharmacodynamics and pharmacokinetics of once-daily TERN-501 as monotherapy or combined with TERN-101, in patients with presumed metabolic dysfunction-associated steatohepatitis.

[Proceedings of The National Academy of Sciences of The United States of America] Investigators employed transcriptomic profilingg and identified elevated hepatocyte proliferation and anabolic metabolism gene signatures during lactation, consistent with the liver being a major producer of substrates needed for milk production.

[Nature Cell Biology] Researchers demonstrated that lactate dehydrogenase B facilitates intratumoural CD8⁺ T cell disulfidptosis and exhaustion, leading to impaired antitumour immunity.